Transaction DateRecipientSharesTypePriceValue
8th October 2020Capital Management, L.P. Ra167,661Open or private sale$50.69$8,498,065.45
7th October 2020Capital Management, L.P. Ra98,597Open or private sale$50.95$5,023,527.01
30th September 2020Capital Management, L.P. Ra124,656Open or private sale$50.27$6,265,871.24
29th September 2020Capital Management, L.P. Ra950,000Open or private purchase$18.00$17,100,000.00
29th September 2020Capital Management, L.P. Ra760,265Conversion of derivative$0.00
29th September 2020Capital Management, L.P. Ra80,707Open or private sale$52.08$4,202,986.51
24th September 2020Capital Management, L.P. Ra473,327Open or private purchase$4.61$2,182,037.47
21st September 2020Capital Management, L.P. Ra2,145,045Conversion of derivative$0.00
21st September 2020Capital Management, L.P. Ra660,000Open or private purchase$19.00$12,540,000.00
17th September 2020Capital Management, L.P. Ra1,300,000Open or private purchase$28.00$36,400,000.00
Wave Life Sciences Ltd.
Wave Life Sciences Ltd. logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Wave Life Sciences Ltd. focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012.

Ticker: WVE
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1631574
Employees: 301
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $94 M (0%)
Other Assets, Current: $16 M (0%)
Assets, Current: $147 M (-20%)
Property, Plant and Equipment, Net: $33 M (-8%)
Assets: $204 M (-28%)
Accounts Payable, Current: $14 M (53%)
Liabilities, Current: $110 M (-6%)
Other Liabilities, Noncurrent: $2 M (-11%)
Liabilities: $201 M (-5%)
Common Stock, Value, Issued: $552 M (2%)
Common Stock, Shares, Issued: $36 M (4%)
Retained Earnings (Accumulated Deficit): $621 M (16%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $278 Th (4%)
Stockholders' Equity (Parent): $4 M (0%)
Liabilities and Equity: $204 M (-28%)
Revenue: $3 M (-57%)
Research and Development: $31 M (-56%)
General and Administrative Expenses: $10 M (-56%)
Operating Income/Loss: $39 M (-56%)
Other Income, net: $2 M (198%)